Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168343 | 1.00 | ACE (0.38) | ACEF2 | |
| SCHEMBL21144509 | 1.00 | ACE (0.38) | ACEF2 | |
| SCHEMBL21168297 | 1.00 | ACE (0.38) | ACEF2 | |
| SCHEMBL25476913 | 0.92 | F2 (0.33) | ACEF2 | |
| SCHEMBL21168347 | 0.91 | ACE (0.40) | ACE | |
| SCHEMBL21168492 | 0.90 | ACE (0.39) | ACEF2 | |
| SCHEMBL21168250 | 0.90 | ACE (0.40) | ACE | |
| SCHEMBL21168251 | 0.90 | ACE (0.40) | ACE | |
| SCHEMBL21998929 | 0.89 | BMP1 (0.33) | ACE | |
| SCHEMBL21168298 | 0.88 | BMP1 (0.33) | ACEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565515-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-03 | — | — | US | disclosed |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-11274123-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-15 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| EP-3737401-A1 | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF CD47 SIGNALLING PATHWAYS | Aurigene Discovery Technologies Limited (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274123-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling | CD47, HIF1AN, PIK3R5 | ACE 4810/4885F2 4703/4885 |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | ACE 4818/4885F2 4697/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885F2 4693/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885F2 4693/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | ACE 4810/4885F2 4703/4885 |
| US-12565515-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways | CD47, MSR1, ARG1 | ACE 4835/4885F2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.